<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034189</url>
  </required_header>
  <id_info>
    <org_study_id>200803088M</org_study_id>
    <nct_id>NCT01034189</nct_id>
  </id_info>
  <brief_title>Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer</brief_title>
  <official_title>A Phase II Study of Combining Cetuximab Plus Twice Weekly Paclitaxel/Cisplatin Concurrent Chemoradiotherapy (TP-CCRT) Followed With or Without Esophagectomy for Loco-regional Esophageal Squamous Cell Carcinoma (ESCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent
      chemoradiotherapy (TP-CCRT) as the adjunctive therapy before esophagectomy or as a definitive
      CRT would improve the therapeutic efficacy of TP-CCRT in patients with loco-regional
      esophageal squamous cell carcinoma (ESCC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent
      chemoradiotherapy as the adjunctive therapy before esophagectomy or as a definitive CRT would
      improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal
      squamous cell carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the clinical response rate in patients with loco-regional esophageal squamous cell carcinoma treated with cetuximab combined with twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (C-TP-CCRT, 40 Gy).</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response (pCR).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity of cetuximab combined with twice weekly TP-CCRT, followed by surgery.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Targeted therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).</description>
    <arm_group_label>Targeted therapy</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.</description>
    <arm_group_label>Targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.</description>
    <arm_group_label>Targeted therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.</description>
    <arm_group_label>Targeted therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically proven squamous cell carcinoma of esophagus.

          2. Loco-regional diseases, which are defined by TNM system of American Joint Committee on
             Cancer (AJCC) Cancer Staging System (6th edition) in 2002, fulfilling one of the
             following criteria:

             A. T3, N0, M0; B. T1-3, N1, M0; C. T1-3 or N0-1, M1a will be eligible provided the
             lesions could be covered by appropriate radiation fields.

          3. Age ≥ 18 years old.

          4. Performance status ECOG 0~2.

          5. Adequate bone marrow reserves, defined as:

             A. white blood cells (WBC) ≥ 4,000/µl or neutrophil count (ANC) ≥ 2,000/µl; B.
             platelets ≥ 100,000/µl.

          6. Adequate liver function reserves, defined as:

             A. hepatic transaminases ≤ 2.5 x upper limit of normal (ULN); B. serum total bilirubin
             ≤ 1.5 x upper limit of normal (ULN).

          7. Adequate renal function: Creatinine ≤1.5 mg/dl

          8. Written informed consent.

        Exclusion Criteria:

          1. Invasion to surrounding organ (T4 disease).

          2. Distant metastasis, except M1a disease listed in the inclusion criteria 2-C.

          3. Adenocarcinoma of gastroesophageal (GE) junction.

          4. Prior thoracic irradiation.

          5. Synchronously diagnosed squamous cell carcinoma of aerodigestive way, other than
             esophageal cancer.

          6. Prior malignancy, except for the following:

             A. adequately treated basal cell or squamous cell skin cancer; B. in-situ cervical
             cancer; C. Note: previously treated aerodigestive squamous cell carcinoma is not
             allowed.

          7. Significant co-morbid disease, which prohibit the conduction of chemotherapy,
             concurrent chemoradiotherapy, or radical surgery, such as active systemic infection,
             symptomatic cardiac or pulmonary disease, or psychiatric disorders.

          8. Estimated life expectancy less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yung-Chie Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chih-Hung Hsu, M.D., Ph.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>67680</phone_ext>
    <email>chihhunghu@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Hung Hsu, M.D., Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>67680</phone_ext>
      <email>chihhunghsu@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Hung Hsu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>December 16, 2009</last_update_submitted>
  <last_update_submitted_qc>December 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chih-Hung Hsu / Department of Oncology</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

